Integrates into current practices

Consistent Q3W Dosing for the Duration of Treatment

Infusion schedule every 3 weeks 2

Based on dosing schedule from IMpower133. Visualization of vials is illustrative and does not represent actual vial usage.

  • During induction phase, TECENTRIQ should be administered by IV infusion first, followed by carboplatin, then etoposide
  • Administer the initial infusion of TECENTRIQ over 60 minutes; if the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes
  • Do not administer TECENTRIQ as an IV push or bolus
  • Do not co-administer other drugs through the same IV line
  • Refer to the respective Prescribing Informations for carboplatin and etoposide for recommended dosing information

Dosage modifications from the TECENTRIQ Prescribing Information 2*

Adverse reaction Severity of adverse reaction
Dosage modifications
Pneumonitis Grade 2 Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 3 or 4 Permanently discontinue
Hepatitis AST or ALT >3 and ≤8 times ULN or total bilirubin >1.5 and ≤3 times ULN
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
AST or ALT >8 times ULN or total bilirubin >3 times ULN
Permanently discontinue
Colitis or diarrhea Grade 2 or 3
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 4
Permanently discontinue
Endocrinopathies Grade 2, 3, or 4
Withhold dose until grade 1 or resolved and clinically stable on hormone replacement therapy
Other immune-mediated adverse reactions involving a major organ Grade 3 Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 4 Permanently discontinue
Infections Grade 3 or 4 Withhold dose until grade 1 or resolved
Infusion-related reactions Grade 1 or 2 Interrupt or slow the rate of infusion
Grade 3 or 4 Permanently discontinue
Persistent grade 2 or 3 adverse reaction (excluding endocrinopathies) Grade 2 or 3 adverse reaction that does not recover to grade 0 or 1 within 12 weeks after last TECENTRIQ dose
Permanently discontinue
Inability to taper corticosteroid Inability to reduce to less than or equal to prednisone 10 mg per day (or equivalent) within 12 weeks after last TECENTRIQ dose
Permanently discontinue
Recurrent grade 3 or 4 adverse reactions Recurrent grade 3 or 4 (severe or life-threatening) adverse reactions
Permanently discontinue


ALT=alanine aminotransferase; AR=adverse reaction; AST=aspartate aminotransferase; AUC=area under the concentration-time curve; IV=intravenous; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; q3w=every 3 weeks; ULN=upper limit of normal.

*Refer to the respective Prescribing Informations for carboplatin and etoposide for dosage modifications and AR management.
NCI CTCAE v4.0.
Including, but not limited to, hypophysitis, adrenal insufficiency, hyperthryroidism, and type 1 diabetes mellitus.